Cell Source, Inc. (CLCS) Research

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.

Market snapshot

Symbol
CLCS
Price
$0.78
Day change
+0.41%
Market cap
$35.2M
P/E ratio
-6.86x
52-week range
0.2322-2.25
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AccuStem Sciences Limited (ACMSY)
  • Gemina Laboratories Ltd. (GLABF)
  • Hemostemix Inc. (HMTXF)
  • Hadasit Bio-Holdings Ltd (HSITF)
  • Propanc Biopharma, Inc. (PPCB)
  • Quest PharmaTech Inc. (QPTFF)
  • Sirona Biochem Corp. (SRBCF)
  • Synairgen plc (SYGGF)

Recent insider activity

  • Verstraete George — trade (0 shares) on 2022-03-10
  • Soave Darlene — J-Other (800000 shares) on 2021-08-09
  • ZOLTY DAVID — J-Other (4860 shares) on 2021-06-30
  • Soave Darlene — J-Other (59507 shares) on 2021-06-30
  • Brown Dennis M — J-Other (2976 shares) on 2021-06-30

Open Cell Source, Inc. (CLCS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.